{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-22-000157","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.143645+00:00","generated_at":"2026-06-24T04:38:28.325052+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Artivion Q2 revenue $80.3M (+6% GAAP, +9% CC); net loss widens to $4.3M","bullets":["Revenue $80.3M vs $76.1M YoY; constant currency growth of 9%.","GAAP net loss $4.3M ($0.11/sh) vs $2.2M ($0.06) YoY; non-GAAP net loss $1.3M ($0.03).","Aortic stent graft revenue up 23% CC; On-X revenue up 12% CC; Asia Pacific +38% CC.","Full-year 2022 constant currency revenue growth guidance reaffirmed at 9%-11%.","Enrolled first patients in US AMDS clinical trial (PERSEVERE); expects FDA PMA approvals for PROACT Mitral and PerClot this year."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-22-000157","json":"https://secwatch.observer/filing/0000784199-22-000157.json","markdown":"https://secwatch.observer/filing/0000784199-22-000157.md","text":"https://secwatch.observer/filing/0000784199-22-000157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000157/0000784199-22-000157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419922000157/aort-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:38:28.325052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}